Compare Piramal Healthcare with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs GSK PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES GSK PHARMA PIRAMAL ENTERPRISES/
GSK PHARMA
 
P/E (TTM) x 13.5 51.1 26.5% View Chart
P/BV x 0.9 10.8 8.0% View Chart
Dividend Yield % 2.1 1.5 140.0%  

Financials

 PIRAMAL ENTERPRISES   GSK PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
GSK PHARMA
Mar-19
PIRAMAL ENTERPRISES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3033,595 91.9%   
Low Rs1,7971,253 143.4%   
Sales per share (Unadj.) Rs716.5184.7 388.0%  
Earnings per share (Unadj.) Rs79.726.3 303.1%  
Cash flow per share (Unadj.) Rs107.929.2 370.0%  
Dividends per share (Unadj.) Rs28.0020.00 140.0%  
Dividend yield (eoy) %1.10.8 133.1%  
Book value per share (Unadj.) Rs1,477.5126.3 1,169.7%  
Shares outstanding (eoy) m184.45169.40 108.9%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.613.1 27.1%   
Avg P/E ratio x32.092.2 34.7%  
P/CF ratio (eoy) x23.683.1 28.4%  
Price / Book Value ratio x1.719.2 9.0%  
Dividend payout %35.176.1 46.2%   
Avg Mkt Cap Rs m470,292410,626 114.5%   
No. of employees `0007.85.0 157.7%   
Total wages/salary Rs m22,5045,372 418.9%   
Avg. sales/employee Rs Th16,899.46,306.7 268.0%   
Avg. wages/employee Rs Th2,877.71,083.1 265.7%   
Avg. net profit/employee Rs Th1,879.9898.0 209.4%   
INCOME DATA
Net Sales Rs m132,15331,281 422.5%  
Other income Rs m3,1281,023 305.7%   
Total revenues Rs m135,28132,304 418.8%   
Gross profit Rs m66,2906,009 1,103.2%  
Depreciation Rs m5,202486 1,070.3%   
Interest Rs m44,0976 734,956.7%   
Profit before tax Rs m20,1196,540 307.6%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m8,6112,373 362.9%   
Profit after tax Rs m14,7014,454 330.1%  
Gross profit margin %50.219.2 261.1%  
Effective tax rate %42.836.3 118.0%   
Net profit margin %11.114.2 78.1%  
BALANCE SHEET DATA
Current assets Rs m122,74220,061 611.8%   
Current liabilities Rs m310,81014,543 2,137.2%   
Net working cap to sales %-142.317.6 -806.7%  
Current ratio x0.41.4 28.6%  
Inventory Days Days2357 40.6%  
Debtors Days Days3914 276.2%  
Net fixed assets Rs m116,90414,343 815.1%   
Share capital Rs m3691,694 21.8%   
"Free" reserves Rs m272,16119,704 1,381.2%   
Net worth Rs m272,53021,398 1,273.6%   
Long term debt Rs m270,1962 13,509,810.0%   
Total assets Rs m856,26139,113 2,189.2%  
Interest coverage x1.51,091.0 0.1%   
Debt to equity ratio x1.00 1,060,751.2%  
Sales to assets ratio x0.20.8 19.3%   
Return on assets %6.911.4 60.2%  
Return on equity %5.420.8 25.9%  
Return on capital %12.431.9 38.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,200534 2,846.5%   
Fx outflow Rs m4,8897,091 68.9%   
Net fx Rs m10,312-6,557 -157.3%   
CASH FLOW
From Operations Rs m-115,9753,994 -2,903.9%  
From Investments Rs m-8,265-1,433 576.6%  
From Financial Activity Rs m107,525-3,584 -3,000.5%  
Net Cashflow Rs m-16,650-1,023 1,627.3%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 4.0 10.2 39.2%  
FIIs % 26.6 23.8 111.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 15.4 107.1%  
Shareholders   93,274 102,036 91.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT  SUVEN LIFESCIENCES  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

DHFL Saga, Falling Passenger Vehicle Sales, and Top Cues in Focus Today(Pre-Open)

Indian share markets witnessed buying interest on Friday and ended their volatile trading session on a positive note.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 11, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - DR. DATSONS LABS COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS